CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
January 22, 2020
 Thanks to all of the CCTG sites who participated, making Canada one of the top 10 accruing countries globally and responsible for a quarter of the North American patients enrolled on the trial. As of December 2019 the final international accruals were 518 patients (target: 500) with 29 enrolled patients from Canada. Read More |
 MAC25, A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer, has been centrally activated.
|
 The Canadian Cancer Society (CCS) is excited to launch the CCS Emerging Scholar Award program, aimed at establishing and advancing promising early career scientists and clinician scientists from across Canada with a focused commitment to undertaking cancer research. Through the CCS Emerging Scholar Award program, early career investigators will develop their cancer research programs in Canada and pursue important scientific advances of the highest quality and potential for impact. Read More |
Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical TrialsPublished: January 22, 2020Category: Publications  A recently published article in the American Journal of Clinical Pathology about the submission of tumour blocks for NCTN trials is the result of work done by the Group Banking Committee of the US NCI which CCTG is a charter member.(Publication) Read More |
January 08, 2020
 REC.3 (NCT02761057), A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005],Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET), has been closed to accrual after completion of target accrual. Treatment and follow-up of accrued patients will continue according to the protocol. Read More |
 SC26 Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia has been centrally activated. Read More |
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Read More |
 MAC7 (NCT00075764) trial: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer has been permenantly closed. Objectives: To compare time to tumour progression in post-menopausal women with metastatic breast cancer treated with anastrozole versus anastrozole and fluvestrant. For more information please visit the CCTG MAC7 trial page. Read More |